Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas

Peripheral T Cell Lymphoma Clinical Trial

— PTCL-SEQ  

Official title:

Prospective Study of Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06089941
• Other study ID #: CHB23.03
• Status: Not yet recruiting
• Start date: November 2, 2023
• Est. completion date: November 2, 2026

Study information

• Verified date: October 2023
• Source: Centre Henri Becquerel
• Contact: Vincent Camus
• Phone: +33232082947
• Email: vincent.camus[@]chb.unicancer.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of genes (NGS), in a population of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL).

Description:

Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of diseases resulting from the clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas and patients with these lymphomas have among the worst 5-year relative survivals (36%-56%, depending on prognostic factors). There are no biomarkers validated in PTCL.

Low pass whole genome sequencing (lpWGS) is an innovative molecular biology technique capable of detecting variations in the number of gene copies in patients' blood, which is a reflection of the quantity of tumor cells in the patient, lymphoma cells carrying numerous gains and deletions of certain genes at the somatic level. lpWGS is inexpensive, requires small quantities of DNA, targets the entire genome, is less time-consuming than other techniques for studying ctDNA and preliminary data in lymphomas have shown the interest of this technique. The investigators hypothesize that this study of ctDNA in PTCL will be relevant, sensitive and very informative for monitoring patients with the lpWGS technique combined with a panel of genes targeted in depth by NGS that the investigators propose to implement. This is a multicenter, prospective study, based on biological samples and clinical and imaging data to be collected.

This study will be offered to each patient suffering from PTCL, including T/NK lymphomas (NKTL) with systemic involvement (excluding cutaneous T-cell lymphomas) having an indication for systemic treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 45
• Est. completion date: November 2, 2026
• Est. primary completion date: November 2, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 or over

• Newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL), including T/NK lymphoma (NKTL)

• Pre-therapeutic FDG PET-CT already performed

• Signed informed consent

• Patients affiliated with or beneficiaries of a health insurance plan

Exclusion Criteria:

• Cutaneous T-cell lymphomas without systemic involvement

• Pregnant or breastfeeding women

• For newly diagnosed patients: patient who has already started the first systemic treatment for their lymphoma (apart from pre-phase corticosteroid therapy which is authorized)

• For patients in a relapsed/refractory situation: Patient who has already started the new specific line of lymphoma treatment planned for the current relapsed/refractory situation (apart from pre-phase corticosteroid therapy which is authorized)

• Lack of patient consent

• Patient whose weight is less than 30 kg

• Protected adult or deprived of freedoms (under guardianship or curatorship)

• Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographic problem, etc.).

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Peripheral T Cell Lymphoma

Intervention

Other:
• circulating tumoral DNA detection
blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse

Locations

Country	Name	City	State
France	Centre Henri Becquerel	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
Centre Henri Becquerel

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of ctDNA assessement	rate of patients considered informative (i.e. patient with at least one detectable mutation from ctDNA analysis by lpWGS and/or targeted NGS). The main objective will be achieved if the proportion of informative results is at least 90%.	at the inclusion
Primary	Feasibility of ctDNA assessement	rate of patients considered informative (i.e. patient with at least one detectable mutation from ctDNA analysis by lpWGS and/or targeted NGS). The main objective will be achieved if the proportion of informative results is at least 90%.	8 weeks
Primary	Feasibility of ctDNA assessement	rate of patients considered informative (i.e. patient with at least one detectable mutation from ctDNA analysis by lpWGS and/or targeted NGS). The main objective will be achieved if the proportion of informative results is at least 90%.	16 weeks
Secondary	Concordance between ctDNA and tumor mutational profile	Description of the concordance between the mutational profile on the tumor and on plasma ctDNA at diagnosis and at relapse	at the inclusion
Secondary	Progression free survival	Time beetween inclusion and progression	one year
Secondary	Overal survival	Time beetween inclusion and death	one year
Secondary	Imaging assessment by PET-CT	Description of metabolic tumor volume before treatment, and therapeutic response (based on Lugano 2014 criteria) end of treatment	16 weeks